Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

Alma R. Oskarsdottir, Brynja R. Gudmundsdottir, Hulda M. Jensdottir, Bjorn Flygenring, Ragnar Palsson, Pall T. Onundarson

Blood (2021) 137 (20): 2745–2755.

https://doi.org/10.1182/blood.2020008698

Published: 2021

Includes: Supplemental data

Journal Articles

Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments

Alma R. Oskarsdottir, MD, Brynja R. Gudmundsdottir, MS, Pall T. Onundarson, MD

Blood (2018) 132 (Supplement 1): 1239.

https://doi.org/10.1182/blood-2018-99-116731

Published: 2018

Journal Articles

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Alma R. Oskarsdottir, BS, Brynja R. Gudmundsdottir, MS, Olafur S. Indridason, MD MPH, Hulda M. Jensdottir, BS, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Brynjar Vidarsson, MD, Charles W. Francis, MD, Pall T. Onundarson, MD

Blood (2015) 126 (23): 1129.

https://doi.org/10.1182/blood.V126.23.1129.1129

Published: 2015

Journal Articles

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Hulda M. Jensdottir, BS, Brynjar Vidarsson, MD, Brynja R. Gudmundsdottir, MS, Alma R. Oskarsdottir, BS, Olafur S. Indridason, MD MPH, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Charles W. Francis, MD, Pall T. Onundarson, MD

Blood (2015) 126 (23): 1134.

https://doi.org/10.1182/blood.V126.23.1134.1134

Published: 2015

Journal Articles

Monitoring Warfarin with the Fiix-Prothrombin Time Improves Anticoagulation Stability and Long-Term Clinical Outcome. the Fiix-Trial

Pall T. Onundarson, MD, Charles W. Francis, MD, Einar S. Bjornsson, MDPhD, Magnus K. Magnusson, MD, David O. Arnar, MD, Olafur S. Indridason, MD, Sigrun Helga Lund, PhD, Sigurdur J. Juliusson, BS, Hulda M. Jensdottir, Brynja R. Gudmundsdottir, MS

Blood (2014) 124 (21): 347.

https://doi.org/10.1182/blood.V124.21.347.347

Published: 2014

Journal Articles

INR and Vitamin K Dependent Coagulation Factor Fluctuation during Warfarin Initiation and Stable Therapy in Patients Dosed with the Fiix-Prothrombin Time or the Quick Prothrombin Time. the Fiix Trial

Brynja R. Gudmundsdottir, MS, Petur I. Jonsson, Pall T. Onundarson, MD

Blood (2014) 124 (21): 4278.

https://doi.org/10.1182/blood.V124.21.4278.4278

Published: 2014

Journal Articles

Critical Role of Factors II and X During Coumarin Anticoagulation and Their Combined Measurement with a New Prothrombin Time Variant (Fiix-PT),

Pall T. Onundarson, MD, Brynja R. Gudmundsdottir, MS, Charles W. Francis, MD

Blood (2011) 118 (21): 3354.

https://doi.org/10.1182/blood.V118.21.3354.3354

Published: 2011

Journal Articles

Coagulation Induced by Dilute Tissue Factor Depends More Critically on Factor II and X Concentration Than on FVII or FIX

Brynja R. Gudmundsdottir, MSc, Alexia M Bjornsdottir, B.Sc., Pall T. Onundarson, MD

Blood (2008) 112 (11): 4084.

https://doi.org/10.1182/blood.V112.11.4084.4084

Published: 2008

Journal Articles

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Pall T. Onundarson, M.D., Hanna S. Asvaldsdottir, M.Sc., Brynja R. Gudmundsdottir, M.Sc., Benny Sorensen, M.D., Ph.D.

Blood (2008) 112 (11): 4097.

https://doi.org/10.1182/blood.V112.11.4097.4097

Published: 2008

NARROW

Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Monitoring Warfarin with the Fiix-Prothrombin Time Improves Anticoagulation Stability and Long-Term Clinical Outcome. the Fiix-Trial

INR and Vitamin K Dependent Coagulation Factor Fluctuation during Warfarin Initiation and Stable Therapy in Patients Dosed with the Fiix-Prothrombin Time or the Quick Prothrombin Time. the Fiix Trial

Critical Role of Factors II and X During Coumarin Anticoagulation and Their Combined Measurement with a New Prothrombin Time Variant (Fiix-PT),

Coagulation Induced by Dilute Tissue Factor Depends More Critically on Factor II and X Concentration Than on FVII or FIX

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only